Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
December 13 2024 - 3:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December, 2024
Commission File Number: 001-40086
Portage Biotech Inc.
(Translation of registrant’s name into English)
Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British
Virgin Islands, VG1110
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
☒ Form 20-F ☐ Form 40-F
INCORPORATION BY REFERENCE
This report on Form 6-K (including
any exhibits attached hereto) shall be deemed to be incorporated by reference into the registration statement on Form S-8 (File No. 333-275842)
of Portage Biotech Inc. (including any prospectuses forming a part of such registration statement) and to be a part thereof from the date
on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
Alexander Pickett was appointed Chief Executive
Officer of Portage Biotech, Inc (the “Company”), effective December 15, 2024. Further, Mr. Pickett was appointed to the Company’s
Board of Directors, effective December 15, 2024.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PORTAGE BIOTECH INC.
By: |
/s/ Andrea Park |
|
|
Andrea Park |
|
|
Chief Financial Officer |
|
Portage Biotech (NASDAQ:PRTG)
Historical Stock Chart
From Nov 2024 to Dec 2024
Portage Biotech (NASDAQ:PRTG)
Historical Stock Chart
From Dec 2023 to Dec 2024